Literature DB >> 28743646

Sepsis and septic shock: New definitions, new diagnostic and therapeutic approaches.

Silvano Esposito1, Giuseppe De Simone2, Giovanni Boccia3, Francesco De Caro3, Pasquale Pagliano4.   

Abstract

Sepsis and septic shock are common life-threatening pathologies associated with high mortality and substantial costs for healthcare system. Clinical guidelines and bundles for the management of patients with sepsis have recently been updated. Herein, we review the history of sepsis and related conditions definitions from the first consensus conference in 1991 to nowadays, the epidemiologic data resulting from worldwide studies on incidence and mortality, the diagnostic approaches including the microbiological assessment of infection and the use of several prognostic and diagnostic biomarkers and finally we review the main therapeutic measures as the intravenous immunoglobulin therapy and the administration of appropriate antibiotic treatment to provide patients with sepsis a favourable outcome in the antibiotic-resistance era.
Copyright © 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic treatment; Biomarkers; Epidemiology; Sepsis; Septic shock

Mesh:

Substances:

Year:  2017        PMID: 28743646     DOI: 10.1016/j.jgar.2017.06.013

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  23 in total

Review 1.  Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting.

Authors:  Vijay Kumar
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

2.  Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Authors:  Amanda Sparkes; Patrick De Baetselier; Lea Brys; Inês Cabrito; Yann G-J Sterckx; Steve Schoonooghe; Serge Muyldermans; Geert Raes; Richard Bucala; Peter Vanlandschoot; Jo A Van Ginderachter; Benoît Stijlemans
Journal:  FASEB J       Date:  2018-01-25       Impact factor: 5.191

3.  Improving clinical outcomes in sepsis and multiple organ dysfunction through precision medicine.

Authors:  Sanjay Mehta; Sean E Gill
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

4.  Intravenous immunoglobulin for the treatment of intractable cholangitis after Kasai portoenterostomy in biliary atresia patients.

Authors:  Dandan Li; Pei Wang; Ying He; Chunlei Jiao; Didi Zhuansun; Nannan Wei; Jixin Yang; Jiexiong Feng
Journal:  Pediatr Surg Int       Date:  2018-02-21       Impact factor: 1.827

5.  Tussilagone Inhibits the Inflammatory Response and Improves Survival in CLP-Induced Septic Mice.

Authors:  Yun Kyu Kim; Myeong Gu Yeo; Bo Kang Oh; Ha Yeong Kim; Hun Ji Yang; Seung-Sik Cho; Minchan Gil; Kyung Jin Lee
Journal:  Int J Mol Sci       Date:  2017-12-18       Impact factor: 5.923

6.  Mediatory roles of leukotriene B4 receptors in LPS-induced endotoxic shock.

Authors:  Sun-Young Kwon; MyungJa Ro; Jae-Hong Kim
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

7.  Comparison of empirical high-dose and low-dose of meropenem in critically ill patients with sepsis and septic shock: A randomized controlled study protocol.

Authors:  Xiaolin Ye; Fei Wang; Wenqing Zeng; Yueping Ding; Bin Lv
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

8.  A crosstalk between type 2 innate lymphoid cells and alternative macrophages in lung development and lung diseases (Review).

Authors:  Lan-Lan Mi; Yue Zhu; Hong-Yan Lu
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

9.  CD63 and C3AR1: The Potential Molecular Targets in the Progression of Septic Shock.

Authors:  Ning Yu; Xuefang Liu; Dandan Shi; Long Bai; Tianfu Niu; Ya Liu
Journal:  Int J Gen Med       Date:  2022-01-19

10.  Gastrodin alleviates inflammatory injury of cardiomyocytes in septic shock mice via inhibiting NLRP3 expression.

Authors:  Feifei Shao; Lingmin Zhou; Yu Zhang; Hongping Chen; Yu Zhang; Zhihui Guan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-06-09       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.